- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in...
Read More Details
Finally We wish PressBee provided you with enough information of ( ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases )
Also on site :
- Country 'MVP' Refunds Entire Audience Mid-Concert and Fans 'Cannot Believe He Did That'
- Legendary '70s Rock Band’s Song Sparks Fan Theories 50 Years Later
- Trump fija nuevo plazo de negociación de dos semanas y desencadena esfuerzo urgente por reanudar las conversaciones con Irán